Impella Support and Acute Kidney Injury During High-Risk PCI

Results from the cVAD Study™ on Renal Protection Dr. Michael Flaherty presents data on...

New PROTECT III Data Demonstrates Impella® Reduces MACCE at Primary Endpoint

Jeffrey J. Popma, MD, presents new data from ongoing FDA post-approval study for PROTECT II randomized control trial. &n...

What is Restore EF?

Impact on EF at 60-180 days after high-risk PCI with Impella® support Jason Wollmu...

New Clinical Publication: Long-Term Outcomes of Complex, High-Risk PCI Patients

Dr. Shon Chakrabarti shares information on a recent publication from the Journal of Interventional Cardiology by Dr. Francesco...